Skip to main content

Table 1 Mole percentage of fatty acids in H9C2 cell (total cell lysate or mitochondria) after 24 h treatment with 100 μM EPA or 50 μM DHA

From: N-3 polyunsaturated fatty acids decrease levels of doxorubicin-induced reactive oxygen species in cardiomyocytes -- involvement of uncoupling protein UCP2

Fatty acid

Total

Mitochondria

(Mol %)

Control

EPA

DHA

Control

EPA

DHA

C12:0

1.16 ± 0.43

1.55 ± 0.32

1.58 ± 0.24

1.25 ± 0.32

1.19 ± 0.25

1.76 ± 0.33

C14:0

0.60 ± 0.06

0.86 ± 0.06

1.05 ± 0.07

0.98 ± 0.02

0.83 ± 0.04

0.72 ± 0.05

C15:0

0.21 ± 0.06

0.22 ± 0.03

0.74 ± 0.32

0.74 ± 0.19

0.75 ± 0.28

0.86 ± 0.39

C16:0

15.22 ± 2.00

15.06 ± 1.98

15.89 ± 1.86

18.94 ± 1.89

15.32 ± 2.11*

15.56 ± 1.54*

C:16:1 t

5.23 ± 1.18

5.16 ± 0.98

3.83 ± 1.18

5.73 ± 1.18

5.63 ± 0.26

5.83 ± 0.98

C16:1

2.86 ± 0.98

1.22 ± 0.81

0.97 ± 0.81

2.65 ± 0.90

2.65 ± 0.60

3.45 ± 1.86

C17:0

1.19 ± 0.23

1.52 ± 0.31

1.99 ± 0.23

1.45 ± 0.32

1.58 ± 0.26

2.49 ± 0.23

C18:0

21.82 ± 3.72

20.15 ± 3.56

19.36 ± 3.92

22.76 ± 1.72

18.73 ± 2.25*

18.36 ± 3.72*

C18:1

14.50 ± 1.06

12.69 ± 1.04*

12.50 ± 1.06*

13.40 ± 1.86

9.04 ± 2.02*

10.95 ± 2.06*

C:18:1 n-7

6.24 ± 0.98

5.06 ± 0.86

5.24 ± 0.95

5.31 ± 0.99

5.78 ± 0.67

5.44 ± 1.80

C18:2 t n-6

2.35 ± 0.46

2.26 ± 0.46

2.35 ± 0.84

3.86 ± 0.86

3.35 ± 0.76

3.35 ± 0.46

C18:2 n-6

2.97 ± 0.43

2.65 ± 0.34

2.40 ± 0.43

2.28 ± 0.58

2.59 ± 0.37

2.40 ± 0.73

C18:3 n-3

0.27 ± 0.17

0.37 ± 0.25

1.26 ± 0.87

0.17 ± 0.04

0.65 ± 0.25

0.67 ± 0.27

C20:0

0.31 ± 0.32

0.56 ± 0.12

0.66 ± 0.32

0.12 ± 0.02

0.18 ± 0.04

0.65 ± 0.32

C20:1

0.37 ± 0.03

0.38 ± 0.04

0.15 ± 0.03

0.24 ± 0.01

0.22 ± 0.02

0.87 ± 0.43

C20:2

1.79 ± 0.31

1.49 ± 0.28

1.15 ± 0.35

1.12 ± 0.05

1.36 ± 0.04

1.15 ± 0.41

C21:0

0.61 ± 0.26

0.51 ± 0.08

0.51 ± 0.26

1.06 ± 0.02

1.52 ± 0.21

1.17 ± 0.06

C20:3 n-6

1.14 ± 0.26

0.97 ± 0.17

1.02 ± 0.21

0.85 ± 0.18

0.93 ± 0.20

0.54 ± 0.06

C20:4 n-6

8.56 ± 1.15

6.67 ± 1.05*

5.59 ± 1.25*

7.67 ± 1.15

5.04 ± 0.19*

4.89 ± 0.25*

C20:3 n-3

0.65 ± 0.15

1.22 ± 0.39

0.90 ± 0.21

0.84 ± 0.19

0.70 ± 0.16

1.44 ± 0.59

C20:5 n-3

0.94 ± 0.25

5.52 ± 1.13*

0.91 ± 0.13

0.72 ± 0.13

5.52 ± 1.23*

0.91 ± 0.13

C23:0

1.14 ± 0.36

0.77 ± 0.56

0.99 ± 0.24

0.32 ± 0.15

0.29 ± 0.12

0.54 ± 0.36

C24:0

0.91 ± 0.13

0.73 ± 0.13

0.84 ± 0.25

0.58 ± 0.15

0.42 ± 0.14

0.99 ± 0.43

C22:5 n-3

3.18 ± 0.88

5.99 ± 1.23*

3.60 ± 0.48

3.05 ± 0.98

10.22 ± 2.08*

3.45 ± 0.96

C22:6 n-3

3.45 ± 0.96

2.97 ± 0.99

13.54 ± 2.89*

3.90 ± 0.56

4.24 ± 0.36

10.65 ± 1.23*

C24:1

1.91 ± 0.12

1.70 ± 0.19

1.54 ± 0.23

0.41 ± 0.11

0.28 ± 0.13

0.51 ± 0.23

n-3/n-6 PUFA

0.56 ± 0.08

1.35 ± 0.14*

1.85 ± 0.19*△

0.59 ± 0.09

1.71 ± 0.18*

1.35 ± 0.15*△

  1. All data are the mean ± S. D. for three separate experiments. PUFA: polyunsaturated fatty acids. *:p <0.05 as compared to the corresponding control; *:p <0.05 compared to the corresponding EPA treatment.